Randox Laboratories and Roquefort Therapeutics Collaborate to Develop Midkine Cancer Antibodies

Home - antibodies

Randox Laboratories and Roquefort Therapeutics Collaborate to Develop Midkine Cancer Antibodies

Randox and Roquefort Therapeutics collaborate to develop midkine cancer antibodies

Randox Laboratories collaborate with Roquefort Therapeutics, an LSE market listed biotech company, dedicated to developing first in class medicines in the high value, high growth oncology market. The partnership is focused on the field of medical diagnostics only, in relation to Roquefort’s Midkine antibody portfolio.

The collaboration Randox will allow to utilise Roquefort’s Midkine antibodies in the field of medical diagnostics. Randox will therefore engage with Roquefort in research programmes to identify new cancer diagnostics that will be treatable with the companies Midkine products.

Why this partnership is important?

Midkine is a herapin binding protein, known for being important in embryonic development. While normally undetected in healthy adults, it is often highly expressed in cancer, inflammatory conditions and autoimmune disorders. Extensive research has revealed that blocking Midkine with antibodies can help slow tumour growth, reduce metastasis and overcome treatment resistance.

Within the partnership, Randox focuses on medical diagnostics to detect cancers expressing Midkine, produce the diagnostics essential for clinical trials and help Roquefort Therapeutics remain focused on developing first in class oncology medicines.

Randox are highly committed to preventative healthcare through early and more accurate diagnostics therefore this partnership with Roquefort Therapeutics is vitally important. Early diagnosis significantly increases a patient’s chance of survival thus using medical diagnostics to identify patients with cancer expressing Midkine is essential to the development of first-in-class cancer medicines and the future of cancer treatments.

When talking about the partnership, Dr Peter Fitzgerald, Managing Director of Randox said

Randox are committed to the promotion of preventative healthcare through early, more accurate diagnosis, and we are delighted to partner with Roquefort to utilise their Midkine antibodies in our comprehensive suite of diagnostics capabilities. Midkine is highly expressed in cancer and by enabling earlier diagnosis of patients we can help improve both quality of life and the clinical outcome” 

 

About Roquefort Therapeutics

Roquefort Therapeutics is a cancer focused biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort successfully acquired Lyramid Pty Ltd, a leader in the development of medicines for a new therapeutic target, Midkine and has since developed a leadership position in Midkine intellectual property.

Roquefort Therapeutics’ focused portfolio consists of four fully funded, novel patent protected, pre-clinical, anti-cancer medicines that include:

  • Midkine antibodies with significant in vivo efficacy and toxicology studies
  • Midkine RNA therapeutics with novel anti-cancer gene editing action
  • MK cell therapy with direct NK-mediate anti-cancer action and
  • SiRNA targeting novel STAT-6 target in solid tumour showing significant in VIVO efficacy.

For more information, please contact market@randox.com


Antibodies & Human Recombinant Proteins

Randox Biosciences is a world-leading primary manufacturer of high quality monoclonal and polyclonal antibodies, antibody fragments and human recombinant proteins. Our team of scientists possess unrivalled expertise which enables us to provide you with a comprehensive suite of products and services dedicated to advancing biopharmaceutical research and diagnostics.

Product Portfolio

Randox Biosciences offers an extensive portfolio of over 900 products for a multitude of R&D applications including more than 500 monoclonal and polyclonal antibodies and over 140 human recombinant proteins as well as antibody fragments, buffers & diluents and plasma.

Monoclonal Antibodies

  • Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; cardiovascular/cerebrovascular and metabolic/Nutrition
  • Drugs of abuse: Alcohol, anti-depressants, barbituates, hallucinogens, opiates, stimulants
  • Drug Residues: antimicrobial drugs, growth promoters, mycotoxins

Polyclonal Antibodies 

  • Biochemical markers: Biochemical messengers, fatty acid binding proteins and products with applications in the following therapeutic areas; Immunology, Oncology, Cardiovascular/Cerebrovascular and Metabolic/Nutrition
  • Drugs of abuse: Alcohol, Analgesics, Anti‑depressants, Barbituates, Benzodiazepines, Hallucinogens, Opiates, Sedatives, Stimulants, Synthetic Drugs, Therapeutic drugs
  • Drug Residues: Anti-inflammatory Drugs, Antimicrobial Drugs, Anti-Parasitic Drugs, Growth Promoters, Mycotoxins

Recombinant Antibody Fragments

  • Single chain variable fragment (scFvs)
  • Single domain antibodies (sdAbs)

Frozen Human Plasma

  • Available in three formats (Male, Female and Mixed Gender)
  • Highly screened for; HIV, Hepatitis B+C, HTLV I + II, Syphilis, CMV and Procleix WNV

Human Recombinant Proteins (E.Coli & Mammalian)

  • Adhesion Molecules
  • Chemokines
  • Cytokines
  • Proteases
  • Tumour markers

Buffers & Diluents

  • Complementary range available

Key Features & Benefits

  • All products manufactured at our ISO 13485 accredited UK manufacturing plant
  • Product range of over 900 products
  • 30 years’ experience in raw material manufacture and assay development
  • Many unique and novel products including designer drugs, Mycotoxins and oncology markers
  • As our host animals are sheep, our antibodies have higher sensitivity and specificity
  • Excellent reproducibility between lot numbers
  • Products reflect the components used in-house in the production of Randox diagnostic products and research programs
  • Highly experienced in developing difficult targets (i.e. small molecules and novel biomarkers)
  • Full customisation service available
  • A range of pack sizes available including bulk quantities for commercial development
  • Products can be used in a multitude

Custom Development Services

To meet your precise requirements, Randox Biosciences offer customised antibody generation services to the pharmaceutical and biotechnology industry. Our custom development service, which encompasses antibodies and human recombinant proteins has achieved tremendous success within the biopharmaceutical and diagnostic industries. Key components of our custom service are our range of monoclonal antibodies as well as our recombinant antibody fragments (sdAbs, scFvs, fAbs).

Our customisation service has proven incredibly successful in the research and development industries allowing access our expertise to obtain the antibody and protein most relevant to your line of work. With over 300 highly trained research scientists and over 30 years’ experience in commercial assay development, Randox Biosciences can also provide a tailor-made assay development service to meet your specifications in both a timely and cost-effective manner.

For more information contact: info@Randoxbiosciences.com

 

 

 


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.